DC (dendritic cells) play an important role in the immune system. They invade peripheral tissues to detect harmful antigens, inducing a local immune response. Studies suggest that DCPs (dendritic cell precursors) might be reduced in AMI (acute myocardial infarction); however, the reason for their reduction is unknown yet. In the present study, circulating mDCPs (myeloid DCPs), pDCPs (plasmacytoid DCPs), tDCPs (total DCPs) and serum levels of TNFα (tumour necrosis factor α), IL (interleukin)-2, -4, -5, -6, -10 and -12 were analysed by flow cytometry in blood of patients with NSTEMI [non-STEMI (ST-segment elevation myocardial infarction)] (n = 44) and STEMI (n = 34) compared with controls with excluded CAD (coronary artery disease) (n = 45). Post-mortem myocardial specimens of patients with AMI (n = 12) and healthy myocardium of accident victims (n = 10) were immunostained for mDCs (myeloid dendritic cells) T-cells and macrophages. Compared with controls, in patients with AMI a significant decrease in circulating mDCPs, pDCPs and tDCPs was observed (each P < 0.0001). The extent of the decrease was higher in STEMI than NSTEMI patients. Serum levels were significantly higher in patients with AMI compared with controls for IL-6, -10, -12 and TNFα (each P < 0.03). Immunostaining revealed significantly higher number of DCs, T-cells and macrophages (each P < 0.002) in infarcted than control myocardium. We show that circulating DCPs are significantly reduced in AMI, with a pronounced reduction in STEMI patients. This was accompanied by a significant increase of inflammatory serum cytokines in patients with AMI. Immunohistochemical analysis unravelled that the reduction of circulating DCPs might be due to recruitment into the infarcted myocardium.
INTRODUCTION
DC (dendritic cells) were first described as 'Langerhans cells' in 1868 by Paul Langerhans. In recent times, their origin and function as professional antigen-presenting cells were unravelled [1] .
DCs are sentinels of the innate as well as the adaptive arm of the immune system [2] . They patrol the blood to initiate an immune response against foreign antigens [3] . Owing to the expression of MHC II as well as costimulatory molecules, they are able to stimulate naive, memory and effector T-cells [4] . Therefore it is well known that they play a major role in the pathogenesis of various inflammatory diseases.
There are two different subtypes of DCs: (i) mDCs (myeloid dendritic cells), which are lineage-negative HLA (human leucocyte antigen)-DR-positive, express CD1c, CD11c and CD33, secrete mainly IL (interleukin)-12 upon stimulation, and drive a Th1-polarized immune response; and (ii) pDCs (plasmacytoid DCs), which are lineage-negative HLA-DR-positive, express CD123, CD303 and the IL-3 receptor α chain, produce IFNα (interferon α) upon (viral) activation and induce a Th2 polarization of naive T-cells [5] . In the blood, both subtypes are found as circulating DCPs (dendritic cell precursors) which lack the expression of costimulatory molecules, so that they are unable to activate T-cells. DCs are recruited from the blood into peripheral tissues where they are present in an immature state as sentinels of the immune system, these immature DCs are also known as DCPs [2] . Upon microbial stimulation via TLRs (Toll-like receptors), DCs undergo a maturation process with up-regulation of antigen presenting molecules (MHC I and MHC II), adhesion molecules (CD11a, CD11b, CD50, CD54 and CD58) and co-stimulatory molecules (CD40, CD80 and CD86) [6] , which enables them to activate T-cells.
In 1995, the presence of DCs was first detected in the vascular wall of arteries, and it was suggested that they might be involved in the inflammatory pathogenesis of atherosclerosis [7] . In several studies, a significant decrease in circulating DCPs was reported in patients with stable and unstable CAD (coronary artery disease) [8] [9] [10] [11] [12] [13] . This decrease is thought to be the result of an enhanced recruitment of circulating DCPs into the atheroma in CAD [8] . The number of circulating DCPs was found to be very low in patients with AMI (acute myocardial infarction) [8] but there was no explanation for this phenomenon yet.
AMI is associated with myocardial inflammation leading to further myocardial damage and possibly to heart failure. After AMI, physiological inflammatory response in the myocardium induces self-repair, leading to a stable myocardial scar, whereas a pathological, overwhelming inflammatory response is associated with ventricular remodelling and CHF (chronic heart failure), which is characterized by hypertrophy of the non-infarcted myocardium and alteration of LV (left ventricular) geometry [14] .
Corresponding to the inflammatory hypothesis of myocardial damage in AMI, it was shown that inflammatory markers are predictors of poor outcome of patients with AMI. High levels of TNFα (tumour necrosis factor α) are associated with the severity of myocardial damage and the emergence of heart failure [15] . A study by Cheng et al. [16] showed that higher frequencies of Th1-cells were found after AMI in patients with more severe heart failure [NYHA (New York Heart Association) III and IV] compared with less heart failure (NYHA I and II). Correspondingly, the in-hospital mortality risk of woman after AMI could be stratified by analysing the acute-phase serum protein CRP (C-reactive protein) [17] . CRP is significantly elevated in patients 3 days post AMI, and higher values are associated with heart failure [18] . Furthermore, it was shown that CRP, which is present in atherosclerotic plaques as well as in the serum of patients with CAD, induces maturation and activation of DCs [19] .
After AMI, antigenic particles are released from myocardial necrosis, leading to immune activation and consecutively to prolonged myocardial inflammation. Correspondingly, in blood of patients after AMI autoantibodies against certain cardiac proteins (e.g. actin and myosin) were found [20, 21] . Additionally, it was shown that cells reacting with myosin, can specifically drive myocardial inflammation [14] . Therefore antigen presenting cells are likely to play a crucial role in the autoimmune response after AMI. For example, in 1993, Zhang et al. [22] showed an increase in interstitial DCs in the border zone of rat hearts with experimental AMI. The presence of DCs in the infarcted myocardium was associated with clusters of T-helper cells. The injection of HMGB1 (high-mobility group box 1) improved global function of rat hearts after AMI in association with attenuated accumulation of DCs [23] .
The aim of our present study was to analyse whether circulating mDCPs and pDCPs (plasmacytoid DCPs) are significantly reduced in patients with different stages of AMI [NSTEMI (non-STEMI (ST-segment elevation myocardial infarction) compared with STEMI] due to myocardial recruitment of circulating DCs.
MATERIAL AND METHODS

Patients and controls
Between March 2010 and June 2011, 78 patients with AMI (44 NSTEMI and 34 STEMI) and 45 coronary healthy individuals (angiographically excluded CAD) were enrolled in the present study. Patients with diseases that could interfere with our analysis, including any kind of infections, malignancies, autoimmune diseases, hyperthyroidism and medication with immunosuppressive agents were excluded. Blood samples were drawn from patients with AMI within 24 h after hospital admission. In order to have a short-term follow-up, a couple of patients with AMI were measured again 4 days after initial presentation. For long-term follow-up, some patients seen in our outpatient department were measured at least 6 months after initial presentation.
Routine blood analysis was immediately performed after blood withdrawal according to clinical standards and by flow cytometry. Probes for cytokine analysis were frozen at − 80
• C and analysed later. The patients were divided into the following three subgroups. (i) The control group consisted of subjects who underwent a coronary angiography for AP (angina pectoris)-like symptoms, and CAD was excluded by this method. Patients with typical AP and elevated serum CK (creatine kinase) and cTNI (cardiac troponin I) were classified as AMI, and were subdivided according to the presence or absence of ST-segment elevations (at least 0.2 mV in two or more contigious precordial leads or at least 0.1 mV in the limbs leads) in the initial ECG into the following groups: (ii) NSTEMI and (iii) STEMI. Follow-up data were collected 30 days after AMI by phone interviews.
The study was performed in accordance with the Declaration of Helsinki (2008) and was approved by the institutional ethics committee. All patients gave written informed consent.
Analysis of circulating DCPs by flow cytometry
In the present study, we used a technique for the analysis of circulating mDCPs and pDCPs described by Dzionek et al. [24] and Ito et al. [25] provided in the Blood Dendritic Cell Enumeration kit TM (BDCA kit; Miltenyi Biotec).
Fresh blood samples were collected in tubes containing EDTA. Four-colour staining and FACS analysis were performed as described previously [8] . In brief, 300 μl of blood was mixed with 20 μl of the control cocktail for isotype control and 300 μl of blood was mixed with 20 μl of the anti-BDCAs (blood dendritic cell antigens) cocktail for DCP analysis. Subsequently, 10 μl of dead-cell discriminator was added, and the samples were incubated for 10 min under 60 W light bulb. The erythocytes lysis solution was used to remove erythrocytes, following the fixation of the samples with the fix solution (Miltenyi Biotec).
FACS analysis was performed using FACSCalibur flow cytometer with CellQuest software (Becton Dickinson). Since circulating DCPs comprise only 0.1-1 % of leucocytes, a special gating strategy was used to exactly analyse the number of mDCPs, pDCPs and tDCPs (total DCPs) ( Figure 1 ): defined by FSC (forward scatter) and SSC (side scatter), in region R1, 2×10 5 leucocytes were registered. Region R2 was used to exclude granulocytes according to their high SSC, and lymphocytes, monocytes and dead cells were excluded according to their CD19, CD14 and propidium iodide staining respectively. In regions R3 and R4, circulating mDCPs and pDCPs were detected due to their specific staining for BDCA-1 and BDCA-2 respectively. tDCPs were defined as the sum of cells in region R3 and R4.
In this manner, the relative cell numbers of circulating DCPs were assessed as percentage of leucocytes. In addition, the absolute cell numbers (cells/μl) were calculated using the relative cell numbers multiplied by leucocyte count.
Cytokine analysis
Serum concentrations of IL-2, -4, -5, -6, -10, -12 and TNFα were measured using the BD TM Enhanced Sensitivity CBA (Cytometric Bead Array) Flex Set (BD Biosciences), according to the manufacturer's instructions. Those instructions mention a detection range of cytokine concentration from 274 up to 200 000 fg/ml. Owing to additional probes in the standard row, it is possible to measure concentrations down to 10 fg/ml.
Immunohistochemical analysis
In collaboration with the Institutes of Pathology and Legal Medicine of the University Hospital Jena, myocardial specimens were collected from 12 patients with AMI, who died during hospitalization, and from ten accident victims serving as controls.
For immunohistochemical staining, the following monoclonal antibodies were used: anti-CD209 (1:100 dilution; BD Pharmingen) for mDC; anti-CD3 (1:100 dilution; Miltenyi Biotec) for T-cells and anti-CD68 (1:100 dilution; DakoCytomation) for macrophages. For immunostaining with all antibodies, the catalysed signal amplification kit TM (DakoCytomation) was used. Stained cells were counted in the infarction area of AMI patients at a magnification of ×100 in each of two representative sections (0.2 mm 2 ) using ImageJ software. For controls, corresponding areas were analysed. Negative controls were treated with isotype-matched antibodies. For each patient, median cell numbers were calculated.
Statistical analysis
Values are presented as medians or means. P < 0.05 was considered statistically significant. For normal distribution, statistical analysis was performed using a Student's t test, and for not-normally distributed data the Mann-Whitney rank sum test was used. Correlation analysis was performed using Pearson Product Moment Correlation (normally distributed data) or Spearman rank order test (not-normally distributed data). Categorical clinical data (e.g. atherogenic risk factors, medication and Upper panels, DCP analysis in control patients; middle panels, DCP analysis in patients with AMI; lower panels, isotype control. Region R1, leucocytes were separated from debris and platelets using their FSC and SSC. Region R2 was used to exclude granulocytes by SSC, B lymphocytes by CD19 staining, monocytes by CD14 staining, and dead cells by propidium iodide-staining. In regions R3 and R4, circulating mDCP and pDCP were detected according to their specific BDCA-1 and BDCA-2 staining respectively. gender) were compared between the study groups using χ 2 test or Fisher's exact test depending on sample size.
RESULTS
Study population
Clinical characteristics of patients with STEMI, NSTEMI and control individuals are reported in Table 1 . In the present study, 34 patients with STEMI and 44 patients with NSTEMI were compared with 45 patients with angiographically excluded CAD. Blood was drawn within 24 h after hospital admission. In relation to the onset of symptoms, the median duration was 24 h in both infarction groups with a minimum of 6 h in the NSTEMIand 5 h in the STEMI-group. The longest time interval after onset of symptoms was 42 h in the NSTEMI-and 44 h in the STEMI group. Within the study groups there was no significant difference in DCP levels between the minimum and maximum time points (results not shown).
In all STEMI patients and in 42 of 44 NSTEMI patients, blood was drawn after PCI (percutaneous coronary intervention) procedure. In two NSTEMI patients, blood samples were taken before PCI. DCP values in those two probes were not altered in comparison with the samples taken after the procedure. In addition, we measured circulating DCPs in 6 CAD patients scheduled for PCI before and after the procedure and we found no significant changes in the levels of circulating DCPs before and after PCI (results not shown).
There were no statistically significant differences concerning age, atherogenic risk factors and medication. As expected, compared with the controls, males were significantly observed more often in the STEMI and NSTEMI population. In the STEMI group, we detected a median ST elevation of 0.3 mV in the precordial leads and 0.2 mV in the limb leads.
Patients with AMI (NSTEMI and STEMI) were treated with heparin, aspirin and clopidogrel or prasugrel. PCI was performed in all patients with AMI. Values of CK and cTNI were significantly increased in patients with AMI. Circulating DCPs were measured in 85 % of the cases at the time of peak CK or peak cTNI in the STEMI group and in 88 % of the cases with NSTEMI at peak CK/cTNI. Only in 9 % (STEMI group) and in 7 % (NSTEMI group) was DCP determination done 12 h (median) after peak values. In 6 % (STEMI) and 5 % (NSTEMI) measurement was performed 9 h (median) before peak CK and peak cTNI respectively. A comparison of the corresponding groups revealed no significant differences for different time points of measurement (results not shown). The EF (ejection fraction) was significantly reduced in both AMI groups compared with the controls (P < 0.0001). Significantly elevated levels of CRP and leucocytes were observed in patients with STEMI and NSTEMI compared with the control group, indicating an inflammatory state in those patients. Patients with STEMI and NSTEMI had significantly higher HDL (high-density lipoprotein) levels in comparison with the control group (both P < 0.0001). Other laboratory parameters were not significantly altered between the groups. Follow-up after 30 days revealed no significant differences between the STEMI and the NSTEMI group concerning AP, second PCI, reinfarction, bypass operation and death.
Decrease in circulating mDCPs and pDCPs in STEMI and NSTEMI
In patients with STEMI or NSTEMI, a highly significant decrease in percentages and total numbers of circulating mDCPs, pDCPs and tDCPs was observed compared with the controls (Figure 2 and Table 2 ). In patients with STEMI compared with those with NSTEMI a trend towards a decrease was observed for mDCPs (0.11 compared with 0.14 %, P = 0.01; 8. .0 μmol/l s, P = n.s.). As long as relative as well as absolute numbers were reduced in patients with AMI the possibility that the decrease was caused by a dilution of DCPs via an increase in another PBMC (peripheral blood mononuclear cell) population could be excluded. Five patients were scheduled for short-term followup. After 4 days, we detected a statistically significant re-increase in circulating mDCPs ( + 83 %), pDCPs ( + 77%), as well as tDCPs ( + 75 %). Patients with long-term follow-up were measured 7-12 months after the initial infarction. Again we found a statistically significant increase in circulating mDCPs ( + 88 %), pDCPs ( + 107 %), as well as tDCPs ( + 93 %) in five patients compared with the initial values (Figure 3) . The comparison of short-and long-term data revealed no statistically significant differences between the time points (results not shown). Comparison of short-and long-term data with the control group (mDCPs, 0.21; 
Increase in serum concentrations of IL-2, -5, -6, -10 and -12 and TNFα during AMI
Patients with NSTEMI and STEMI had significantly elevated serum levels of IL-6 (P < 0.0001), IL-10 (P = 0.002), IL-12 (P = 0.04) and TNFα (P = 0.01) compared with the control group. Levels of IL-2 (P = 0.04) and IL-5 (P = 0.005) were significantly elevated in patients with STEMI but not in the NSTEMI group (P = n.s.). IL-4 concentration was not significantly altered between the study groups (P = n.s.). In patients with STEMI compared with those with NSTEMI, a significant increase was observed for IL-6 (P = 0.001) (Figure 4) .
Correlation of circulating DCPs with various serum parameters and EF
To reveal a possible relationship between circulating DCPs and serum parameters, a detailed correlation analysis was performed. We found a significant inverse correlation between CK and circulating mDCPs (r = − 0.50, P < 0.0001), pDCPs (r = − 0.50, P < 0.0001) and tDCPs (r = − 0.56, P < 0.0001). Furthermore, a significant inverse correlation between cTNI and DCPs (mDCPs: r = − 0.53, P < 0.0001; pDCPs: r = − 0.48. P < 0.0001; tDCPs: r = − 0.55, P < 0.0001) was found. CRP was found to be significantly inversely correlated with mDCPs (r = − 0.45, P < 0.0001), pDCPs (r = − 0.35, P < 0.0001), and tDCPs (r = − 0.48, P < 0.0001). IL-6 was also significantly inversely correlated with mDCPs (r = − 0.45, P < 0.0001), pDCPs (r = − 0.47, P < 0.0001) and tDCPs (r = − 0.53, P < 0.0001). The EF was positively correlated with mDCPs (r = 0.44, P < 0.0001), pDCPs (r = 0.30, P = 0.0011) and tDCPs (r = 0.46, P < 0.0001) ( Figure 5 ).
Emergence of DCs, T-cells and macrophages in infarcted myocardium
The clinical characteristics of patients who died after AMI were as follows: median age, 73 years; 75 % males; 50 % STEMI and 50 % NSTEMI; median time from MI to death, 3 days; median cTNI, 54 ng/ml; median CK, 16.5 μmol/l per s; median leucocytes, 14.2 Gpt/l; median CRP, 155 mg/dl; and median creatinine, 125.5 μmol/l. In the infarcted myocardium, we observed significantly higher numbers of mDCs, detected by their specific expression of CD209, compared with healthy control myocardium (78 compared with 33 cells/0.2 mm 2 , P = 0.0002). Furthermore, significantly more macrophages (62 compared with 7.5 cells/0.2 mm 2 , P < 0.0001) 
DISCUSSION
AMI is the most common reason for cardiac injury and CHF. Some of the cardiac repair mechanisms following AMI depend on the activation of inflammatory pathways. DCs play a crucial role in different inflammatory diseases, so they might be involved in the immune reactions following AMI.
In the present study, we investigated the number of circulating DCPs in patients with AMI compared with control patients without CAD. As a main finding, we could demonstrate that circulating mDCPs as well as pDCPs were significantly reduced in patients with STEMI and NSTEMI compared with coronary healthy controls. The reduction in mDCPs ( − 21 %) and tDCPs ( − 15 %) was more pronounced in patients with STEMI, compared with NSTEMI.
In the last few years, in independent studies, a decrease in circulating DCPs was described in patients with stable and unstable CAD [8] [9] [10] [11] [12] [13] 26] . However, there are only two reports concerning circulating DCPs in ACS (acute coronary syndrome) yet [8, 10] . Yilmaz et al. [8] found a significant decrease in circulating mDCPs in patients with stable and unstable AP as well as AMI. However, in that study, it was not possible to detect any significant changes for circulating pDCPs in patients with AMI compared with controls. In contrast, in our present study, we showed a significant decrease in circulating mDCPs as well as pDCPs in patients with STEMI and NSTEMI compared with controls. The reason for this discrepancy might be the smaller patient number in the earlier study. There is only one study reporting an increase in circulating DCPs in patients with CAD [27] . The reason for this contradictory finding may be due to the different Asian genetic background or other technical reasons. However, further investigation of this issue is necessary.
In addition to the decrease in circulating DCPs in peripheral blood, we could detect significantly elevated levels of markers indicative for mDCs in the infarcted myocardium. This leads to the hypothesis that circulating DCPs might be decreased due to their enhanced recruitment and consumption in the infarcted myocardium. The fact that CD 209 staining detects predominately immature mDCs further highlights our theory that precursors of DCs were recruited into the infarcted area soon after AMI. In addition, we found elevated levels of T-cells (CD3 + ) and macrophages (CD68 + ) in the infarcted tissue. As long as DCs are known to be the most potent T-cell activators [28] , it is likely that they induce an immune response soon after AMI. Our results are in concordance with a recently published study, where the emergence of mDCs was investigated in the myocardium of patients after sudden cardiac death [29] . Corresponding to our findings, the presence of mDCs was demonstrated in the infarcted area in several former studies using animal models of AMI [22, 23, 30] . For example, Takahashi and co-workers [23] showed that the injection of HMGB1 in post-infarction rat hearts significantly reduced the number of DCs in the peri-infarct area. Corresponding to AMI, in patients with acute stroke a decrease in circulating DCPs and recruitment into the infarcted brain was shown previously [31] .
The extent of the decrease of mDCPs and tDCPs was statistically higher in patients with STEMI than NSTEMI. The reason for this finding might be that after STEMI a greater infarcted area, often transmural, is observed than after NSTEMI. In consequence, there is more space for DC invasion. In agreement with this hypothesis, there was a significant inverse correlation between markers of myocardial damage (CK and cTNI) and circulating DCPs. Further evidence for this hypothesis is the finding that CRP and IL-6 as inflammatory markers were significantly more increased in patients with STEMI than NSTEMI, and both were significantly inversely correlated with circulating DCPs. Furthermore, the decrease in circulating DCPs was positively correlated with the decrease in EF.
Figure 6 Emergence of mDCs, macrophages and T-cells in infarcted myocardium
CD209
+ DCs, CD68 + macrophages, and CD3 + T-cells in control and infarcted myocardium. Negative (isotype) controls for CD209 + , CD68 + and CD3 + in control and infarcted myocardium.
This finding might strengthen our assumption that enhanced recruitment of circulating DCPs into the infarcted area might be associated with enhanced myocardial inflammation leading to a deterioration of LV function and thus the possible induction of CHF. A significant systemic inflammation and an inverse correlation between circulating DCPs and various inflammatory markers in patients with AMI was observed in previous studies. Yilmaz et al. [8] showed a significant inverse correlation between mDCPs and hsCRP (highsensitivity CRP) as well as mDCPs and IL-6 studying patients with AMI. Additionally, in an earlier in vitro study by Van Vre et al. [19] it was demonstrated that even low levels of CRP activate monocyte-derived DCs enabling them to induce a T-cell response. Cytokines and chemokines such as IL-6 and TNFα were reported to be elevated after infarction. They regulate myocyte survival and induce cellular inflammatory responses [32, 33] . We found a significant up-regulation of IL-6, TNFα, IL-12 and, in addition, of IL-10. Although IL-6, TNFα and IL-12 are markers of a pro-inflammatory response, IL-10 as an anti-inflammatory cytokine is counterbalancing the inflammatory stimuli to avoid an overwhelming immune response after AMI. As long as mDCs are a main source of IL-12 [34] , the up-regulation of this cytokine serves as an indicator for DC activation. It could not be completely excluded that the decrease in circulating DCPs might also be in part the result of reduced differentiation and less release of DCPs from the bone marrow into the blood. In our short-term follow-up, we found a significant increase in circulating DCP levels 4 days after MI. This further highlights our theory that initial reduction is mostly due to myocardial recruitment and less affected by reduced differentiation and release from the common progenitor because in this situation it would take much more time than 1 week until a re-increase. Additionally, in the long-term follow-up which was performed for the first time, we demonstrated that circulating DCPs were significantly elevated compared with the initial measurement.
Several studies investigated cytokine levels associated with DC maturation. The growth factor GM-CSF (granulocyte/macrophage colony-stimulating factor) that is used to generate DCPs in vitro from myeloid progenitors was found to be in similar concentrations in controls and patients with CAD [13] . However, it has been shown that GM-CSF is a key mediator of DC-maturation leading to inflammation in different inflammatory disorders [35] , so that it might be possible that this haematopoetic cytokine plays an important role in DC maturation during inflammation in AMI. Flt3L (fms-like tyrosine kinase 3 ligand) was found to be a key cytokine involved in DC development and release from the bone marrow [36] . Indeed, a recent study showed that plasma levels of Flt3L were significantly reduced in CAD patients and positively correlated with DC levels [13] .
Conclusions
In the present study, we have shown a significant decrease in circulating mDCPs as well as pDCPs in patients with AMI. In addition, we found significantly higher numbers of markers indicative for mDCs and inflammatory cells such as macrophages and T-cells in the infarcted compared with control myocardium. This was accompanied by increased serum levels of inflammatory as well as anti-inflammatory cytokines in patients with AMI. Future studies are required to investigate whether enhanced myocardial recruitment of DCPs following AMI might induce myocardial inflammation leading to enhanced ventricular remodelling and, thus, to CHF. 
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